Abstract
Thalidomide and its immunomodulatory (IMiDs) analogs (lenalidomide, Revlimid, CC-5013; CC-4047, ACTIMID) are a novel class of compounds with numerous effects on the body's immune system, some of which are thought to mediate the anticancer and anti-inflammatory results observed in humans. Thalidomide is currently being used experimentally to treat various cancers and inflammatory diseases. It is approved for the treatment of dermal, reaction from leprosy and is currently in phase III trials for multiple myeloma. Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-α (TNF-α), interleukins (IL) 1β, 6, 12, and granulocyte macrophagecolony stimulating factor (GM-CSF). They also costimulate primary human T lymphocytes inducing their proliferation, cytokine production, and cytotoxic activity thereby increasing the T cells' anticancer activity. They induce an IL-2-mediated primary T cell proliferation with a concomitant increase in IFN-γ production and decrease the density of TNF-α-induced cell surface adhesion molecules ICAM-1, VCAM-1, and E-selectin on human umbilical vein endothelial cells. Thalidomide stimulates the Th-1 response increasing, IFN-γ levels while CC-4047 increased IL-2 as well. Some of the above immunomodulatory activities along with anti-angiogenic, anti-proliferative, and pro-apoptotic properties are thought to mediate the IMiDs' antitumor responses observed in relapsed and refractory multiple myeloma and some solid tumor cancers. This has led to their use in various oncology clinical trials. The second generation IMiD, lenalidomide, has shown potential in treating the bone marrow disorders myelodysplastic syndrome and multiple myeloma. It is currently in phase II and III trials for these diseases respectively with numer-ous phase II trials in other hematologic and solid tumors.
Similar content being viewed by others
References
Teo S, Resztak K, Scheffler M, et al. Thalidomide in the treatment of leprosy.Microbes Infect. 2002;4:1193–1202.
Stephens T, Brynner R.Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine. Cambridge, MA: Perseus Publishing; 2001.
Mellin G., Katzenstein M. The saga of thalidomide: neuropathy to embryopathy with case reports and congenital abnormalities.N Engl J Med. 1962;267:1184–1193.
Kelsey F. Thalidomide update: regulatory aspects.Teratology. 1988;38:221–226.
Newman L, Johnson E, Staples R. Assessment of the effectiveness of animal developmental toxicity testing for human safety.Reprod Toxicol. 1993;7:359–390.
Zeldis J, Williams B, Thomas S, Elsayed M. STEPS™: a comprehensive program for controlling and monitoring access to thalidomide.Clin Ther. 1999;21:319–330.
Raje N, Anderson K. Thalidomide and immunomodulatory drugs as cancer therapy.Curr Opin Oncol. 2002;14:635–640.
Singhal S, Mehta J, Desikan R, et al. Anti-tumor activity of thalidomide in refractory multiple myeloma.N Engl J Med. 1999;341:1565–1571.
Drach J, Kaufman H, Woehrer S, Chott A, Zielinski C, Raderer M. Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma.Proc Am Soc Clin Oncol. 2004;22: Abstract 6583.
Stirling D. Thalidomide and its impact on dermatology.Semin Cutan Med Surg. 1998;17:231–242.
Vasiliauskas E, Kam L, Abreu-Martin M, Papadakis K, Zeldis J, Targan S. An open-label step-wise dose escalating pilot study to evaluate the safety, tolerance and efficacy of low dose thalidomide in the treatment of chronically-active, steroid-dependent Crohns disease.Gastroenterol. 1999;116:A387. Abstract G3637.
Schey S, Cavenagh J, Johnson R, Child J, Oakervee H, Jones RA. UK myeloma forum phase III study of thalidomide: long-term follow-up and recommendations for treatment.Leuk Res. 2003;27:909–914.
Fine H, Wen P, Maher E, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade glioma.J Clin Oncol. 2003;21:2299–2304.
Hwu W, Krown S, Menell J, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.J Clin Oncol. 2003;21:3351–3356.
Maples W, Stevenson J, Sumrall S, Naughton M, Schwartz J. Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide.J Clin Oncol. 2004;22:4082.
Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity.J Support Oncol. 2003;1:194–205.
Corral L, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues.Ann Rheum Dis. 1999;58:(Suppl. 1),1107–1113.
Sampaio E, Sarno E, Gallily R, Cohn Z, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes.J Exp Med. 1991;173:699–703.
Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.Bioorg Med Chem Lett., 1999;9:1625–1630.
Munshi N. Recent advances in the management of multiple myeloma.Semin Hematol. 2004;41:21–26.
Richardson P, Schlossman R, Anderson K. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Blood. 2002;100:3063–3067.
Mufti G, List A, Gore S, Ho A. Myelodysplastic syndrome.Hematology (Am Soc Hematol Educ Program). 2003;:176–199.
List A, Kurtin S, Glinsmann-Gibson B, et al. Efficacy and safety of CC-5013 for treatment of anemia in patients with myelodysplastic syndrome (MDS).Blood. 2003; 102: Abstract 641.
Sison B, Bond T, Amato R, Crawford D, Crighton F. Phase II of CC-4047 in patients with metastatic hormone-refractory prostate cancer.J Clin Oncol. 2004;22:4701.
Corral L, Muller G, Moreira A, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.Mol Med. 1996;2:506–515.
Moreira A, Sampaio E, Zmuidzinas A, Frindt P, Smith K, Kaplan G. Thalidomide exerts its inhibitory action on TNF-alpha by enhancing mRNA degradation.J Exp Med. 1993;177:1675–1680.
Corral L, Haslett P, Muller G, et al. Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF-α.J Immunol. 1999;163:380–386.
Haslett P, Corral L, Albert A, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.J Exp Med. 1998;187:1885–1982.
Bartlett J, Dredge K, Dalgleish A. The evolution of thalidomide and its IMiD® derivatives as anti-cancer agents.Nat Rev Cancer. 2004;4:314–322.
Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.Immunopharmacology. 1996;31:213–221.
Verbon A., Juffermans N, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans.Antimicrob Agents Chemother. 2000;44:2286–2290.
Dredge K, Marriott J, Todryk S, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.J Immunol. 2002;168:3914–3919.
Oliver S. The Th1/Th2 paradigm in the pathogenesis of scleroderma and its modulation by thalidomide.Curr Rheumatol Rep. 2000;2:486–491.
Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.J Pharmacol Exp Ther. 2003;305:1222–1232.
Davies F, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.Blood. 2001; 98:210–216.
D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci USA. 1994;91:4082–4085.
Dredge K, Marriott J, Macdonald C, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.Br J Cancer. 2002; 87:1166–1172.
Gupta D, Treon S, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.Leukemia. 2001;15:1950–1961.
Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analog overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000;96:2943–2950.
Mitsiades N, Mitsiades C, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood. 2002;99:4525–4530.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published: March 22, 2005.
Rights and permissions
About this article
Cite this article
Teo, S.K. Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J 7, 3 (2005). https://doi.org/10.1208/aapsj070103
Received:
Accepted:
DOI: https://doi.org/10.1208/aapsj070103